ASCO 2024 – some Adriatic fears allayed
Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.
ASCO 2024 preview – with more patients Merus claims better efficacy
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
ASCO 2024 preview – Merus’s home run remains unconfirmed
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
Agenus tries again with the FDA
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Merck joins the TIGIT pivotal failure club
Keyvibe-010 fails, but not for the reason you might have expected.
